Stoke：維持「買進」評等，Zorevunersen 推進 SCN1A Dravet 症候群新藥申請且 STK-002 取得進展 (NASDAQ:STOK)
· seekingalpha.com
由於 zorevunersen 達成 Dravet 症候群關鍵里程碑且 STK-002 持續推進，Stoke Therapeutics 維持「買進」評等；其強勁的現金流可支撐至 2028 年。點擊查看更多關於 STOK 股票的資訊。
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...